Innoviva (INVA) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.02 per share a year ago. These figures are ...

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look ...

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago.

Former chemistry teacher Zhong Huijan’s Hansoh Pharmaceutical Group strikes potentially lucrative licensing deals with big ...

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial ...

The quarter saw Amgen lift its total revenue by 12% year over year to $9.6 billion, fueled by double-digit increases in the ...

Novo Nordisk stock is dropping after it posted quarterly earnings. The Danish drugmaker's fight with Pfizer to acquire Metsera is getting more heated.

Hilliard, the HHS spokesperson, told SFGATE on Tuesday that, “Secretary [Robert F.] Kennedy [Jr.] expects the highest ethical ...

Speculative activity surged across the micro-cap landscape during the third quarter, fueled by thematic momentum and outsized ...

Sun Pharma is open to expanding its US manufacturing capabilities in response to the Trump administration's 100% tariff on ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Google’s parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome ...